Leadership Team

When it comes to finding a cure for neurodegenerative diseases, our team won’t take no for an answer. Progress is made possible thanks to the passion and drive of every Amylyx team member.


Executive Team

Josh Cohen
Josh CohenCo-CEO and Co-Founder
Josh Cohen
Josh CohenCo-CEO and Co-Founder

Joshua Cohen co-founded Amylyx Pharmaceuticals in 2013 and continues to serve as its Co-CEO and Co-Founder. Josh has overseen the growth of Amylyx from a dorm-room concept to a clinical stage pharmaceutical company. His research experience includes work both at Brown University and at the National Institute of Standards in Technology. Josh received his BS in biomedical engineering from Brown University.

Justin Klee
Justin KleeCo-CEO and Co-Founder
Justin Klee
Justin KleeCo-CEO and Co-Founder

Justin Klee co-founded Amylyx Pharmaceuticals in 2013 and continues to serve as its Co-CEO and Co-Founder. Along with his co-founder Josh, Justin has overseen the development of Amylyx’s novel platform and therapeutic for neurodegenerative diseases from initial testing through clinical trials. Justin previously did research at Brown University in neural systems and neurophysiology and Alzheimer’s disease at Harvard Medical School. He received his Sc.B in Neuroscience from Brown University.

Kent Leslie
Kent LeslieGlobal Head of R&D and CSO
Kent Leslie
Kent LeslieGlobal Head of R&D and CSO

Kent Leslie joined Amylyx Pharmaceuticals in 2015 and serves as its Chief Scientific Officer. Kent oversees the design and conduct of all preclinical scientific studies and academic collaborations, as well as seeking new therapies and applications. Kent received his M.Sc in Biotechnology from Brown University while completing research in the lab of Dr. Richard Bennett. Prior to receiving his Master’s degree, Kent received Bachelor’s degrees in Biology and Economics from Brown University.

Patrick Yeramian
Patrick Yeramian, MD MBAGlobal Head of Clinical R&D and CMO
Patrick Yeramian
Patrick Yeramian, MD MBAGlobal Head of Clinical R&D and CMO

Dr. Yeramian joined Amylyx as Chief Medical Officer in 2019 bringing to the company more than 30 years of pharmaceutical industry experience. He was previously the consulting medical director for Amylyx, where he has supported the pre-IND and IND filings of AMX0035 for the treatment of amyotrophic lateral sclerosis and Alzheimer’s disease, and has overseen the design and execution of both clinical trials.

Throughout his career Dr. Yeramian has supervised the clinical development of new drugs, biopharmaceuticals, cellular therapy agents and vaccines. He has held prominent roles in the approval of several drug (metronidazole – Flagyl MR®), biological (interferon alpha – Multiferon®, nafarelin – Synarel®) and device (Inerpan®) applications by the FDA and EMA and granting of more than 20 successful INDs and IMPDs. Previously he served as Chief Medical Officer at Viragen, Inc. where he was responsible for the development of global clinical and regulatory strategies and for the implementation of clinical programs worldwide. Earlier in his career, Dr. Yeramian served as Director of clinical research at GD Searle where he supervised the clinical programs for antibiotics, antivirals, sepsis/thrombosis and cancer vaccines. He also previously served as Medical Director of the Vaccine and Gene Therapy Institute in Florida.

Dr. Yeramian holds a Medical Degree from the University of Paris together with a Master of Clinical Science in experimental oncology and a Graduate Degree in molecular virology. He received his Master of Business Administration from Rutgers University. He completed his medical residency in oncology at the Saint-Louis Hospital in Paris.

Margaret Olinger
Margaret OlingerGlobal Head of Commercial and CCO
Margaret Olinger
Margaret OlingerGlobal Head of Commercial and CCO

Margaret Olingerjoins Amylyx after more than a decade at Alexion Pharmaceuticals, where she helped build and lead some of the most successful commercial launches and operations throughout the U.S. and globally for therapies addressing unmet needs in rare and ultra-rare diseases, including Strensiq® and Soliris®. During Ms. Olinger’s tenure at Alexion, she served in various commercial leadership roles, most recently as vice president, head of global Strensiq® therapeutic area, and previously held positions including vice president, U.S. complement business unit leader; vice president, global hematology therapeutic area; vice president, global PNH therapeutic area; and vice president, U.S. and global marketing, a role in which she supported commercialization of Soliris® for PNH across all markets. Prior to Alexion, Ms. Olinger spent nearly 20 years at Bayer Healthcare, serving in various leadership and commercial positions, which culminated in her role as director, executive operations. Ms. Olinger received a Bachelor of Science in Business Administration from Albertus Magnus College and a Master of Business Administration from the University of New Haven

Debra Canner
Debra CannerGlobal Head of Human Resources and CHRO
Debra Canner
Debra CannerGlobal Head of Human Resources and CHRO

Debra Canner joined Amylyx as Global Head of Human Resources in 2019, overseeing the company’s human resource efforts, including talent management, organizational leadership, culture and corporate responsibility.

Throughout her distinguished career as a human resources leader, including chief human resources officer experience at three preeminent life science and technology organizations, Deb brings a strategic yet practical approach to her work. Deb plays a large role in shaping and fostering a culture focused on attracting, retaining and developing bold, collaborative talent that aims to improve the lives those of suffering from disease.

Prior to her CHRO roles at Akamai Technologies, Joslin Diabetes Center, and Haemonetics Corporation, Deb was part of Genzyme, now a fully owned subsidiary of Sanofi, and rose to become the number two HR leader there during a period of significant growth. Since 2013, Deb has been a human resources consultant to leaders of public and private small and emerging growth life science companies with a focus on HR leadership across all areas of Human Resources. Past clients include: Gen9 Bio, CeQur, Joslin Diabetes Center, Juniper Pharmaceuticals, Navitor Pharmaceuticals, Cogen Immune Medicines, and CANbridge Pharmaceuticals.

Deb received a B.A. from the University of Massachusetts, Amherst. She holds a certification in executive leadership development from the Center for Creative Leadership.

Tom Holmes
Tom HolmesGlobal Head of Supply Chain
Tom Holmes
Tom HolmesGlobal Head of Supply Chain

Tom Holmes joined Amylyx in March 2019 as Global Head, Supply Chain, bringing more than 25 years of leadership experience in supply chain, biopharmaceutical manufacturing and program management. Prior to joining Amylyx, Tom was the Senior Director of External Manufacturing at Biogen Inc., a role he held for 10 years. As Senior Director, Tom managed Biogen’s global external manufacturing network and was responsible for driving supply contracting decisions for 11 commercial assets and more than 42 new molecular entities in various stages of clinical development. Tom held several positions at Biogen beginning in 1994 including planning, logistics program management, Launch Lead, and manufacturing. Tom received a Bachelor of Science in Business Administration with a concentration in Management from Salem State University.

Questions?

For inquiries or further information, please do not hesitate to contact us.

Contact Us